Aligos Therapeutics Inc (ALGS) - Total Liabilities
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has total liabilities worth $32.77 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Aligos Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Aligos Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ALGS total asset value.
Aligos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aligos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sun Race Sturmey-Archer Inc
TW:1526
|
Taiwan | NT$960.72 Million |
|
Jade Marvel Group Bhd
KLSE:7043
|
Malaysia | RM24.14 Million |
|
Petratherm Ltd
AU:PTR
|
Australia | AU$466.42K |
|
Pioneer Motor Public Company Limited
BK:PIMO
|
Thailand | ฿255.68 Million |
|
Sangshin Electronics Co. Ltd
KQ:263810
|
Korea | ₩39.13 Billion |
|
Harvard Bioscience Inc
NASDAQ:HBIO
|
USA | $68.87 Million |
|
TOP Engineering Co. Ltd
KQ:065130
|
Korea | ₩200.30 Billion |
|
IT Link
PA:ALITL
|
France | €31.36 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Aligos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Aligos Therapeutics Inc (ALGS) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aligos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Aligos Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.99 Million | -64.68% |
| 2024-12-31 | $99.07 Million | +66.65% |
| 2023-12-31 | $59.45 Million | +38.92% |
| 2022-12-31 | $42.79 Million | -15.49% |
| 2021-12-31 | $50.64 Million | +11.88% |
| 2020-12-31 | $45.26 Million | -78.59% |
| 2019-12-31 | $211.41 Million | +74.03% |
| 2018-12-31 | $121.48 Million | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more